Alere Opts Not to Pursue Initial Public Offering by BBI Diagnostics Group plc

Alere Opts Not to Pursue Initial Public Offering by BBI Diagnostics Group plc

PR Newswire

WALTHAM, Mass., June 18, 2014

WALTHAM, Mass., June 18, 2014 /PRNewswire/ --Alere Inc.(NYSE: ALR) today
announced that it has elected not to proceed at this time with its previously
announced plans to pursue an initial public offering in the United Kingdom of
the ordinary shares of BBI Diagnostics Group plc, or BBI Diagnostics, and
intends to seek greater value for the businesses of BBI Diagnostics than could
be realized under current equity market conditions in the United Kingdom.
Alere remains committed to its previously communicated strategy of divesting
of non-core assets and to the use of proceeds from such divestitures to reduce
its outstanding indebtedness.

About Alere
By developing new capabilities in near-patient diagnosis, monitoring and
health information technology, Alere enables individuals to take charge of
improving their health and quality of life at home. Alere's global leading
products and services, as well as its new product development efforts, focus
on infectious disease, toxicology, cardiology and diabetes. Alere is
headquartered in Waltham, Massachusetts. For more information regarding Alere,
please visit www.alere.com.

SOURCE Alere Inc.

Website: http://www.alere.com
Contact: Doug Guarino, Director of Corporate Relations, 781-647-3900
 
Press spacebar to pause and continue. Press esc to stop.